The facts on Pyrocatechol (1,2-Dihydroxybenzene)

The facts on Pyrocatechol (1,2-Dihydroxybenzene)

No estimates of current numbers of workers exposed to pyrocatechol (1,2-dihydroxybenzene) in the EU are available.
Pyrocatechol is used in solid and liquid form. Since it can penetrate the skin, both inhalation and dermal contact are relevant exposure routes.
The substance is classified under the EU CLP Regulation as a suspected human carcinogen (Category 1B).

Where risks occur

Occupational exposure to pyrocatechol occurs mainly in chemical and pharmaceutical manufacturing, in technical testing and analysis, and in some downstream industries such as surface treatment, electronics, rubber and plastics, and machinery production.
Professionals at highest risk of exposure to pyrocatechol include chemical process operators, distillation, mixing, and tank farm operators as well as maintenance workers, laboratory technicians, and analytical chemists. Electroplating workers, and workers involved in surface treatment and electronics manufacturing may also be exposed.
Exposure is most likely during activities where the substance is handled in open systems or where containment is not fully effective, such as in mixing or blending tasks, in dipping, coating or in surface treatment processes. Additional exposure may occur during maintenance and cleaning operations.

More about the substance

Pyrocatechol is a solid substance at room temperature, typically appearing as a white to brown crystalline solid that may darken on exposure to air. Pyrocatechol dissolves very well in water and in many organic solvents.

Pyrocatechol is not highly flammable or explosive under normal conditions. However, it can form dust when handled as a solid and may generate aerosols or vapours when heated during industrial processes or when used in liquid form.

It is mainly used as an intermediate in the manufacture of other substances and products. The biggest end-use product categories for pyrocatechol include agrochemicals (crop protection products), flavours and fragrances (e.g. vanillin, household fragranced products), pharmaceuticals and rubber/polymer additives for plastics, tires and rubber goods.

Health risks that may occur

Exposure to pyrocatechol can occur via inhalation of dust or vapours and through skin contact.
Short-term exposure can lead to symptoms such as coughing, throat irritation, eye irritation and skin redness or discomfort. Very high exposures (for example, if swallowed) may result in more severe toxic effects. It may also cause allergic skin reactions after repeated exposure.
Long-term exposure may lead to more serious health effects, including an increased risk of cancer, skin depigmentation, chronic dermatitis and respiratory effects.

What you can do

Substitution should be considered as the priority. Where possible, pyrocatechol should be replaced with less hazardous substances or alternative processes that reduce exposure. Possible substitutes for pyrocatechol (catechol) depend on its role: hydroquinone, resorcinol, and pyrogallol can replace it in some similar chemical or redox applications; gallic acid or tannic acid may work for metal-chelating uses; and ascorbic acid or sodium borohydride can sometimes substitute pyrocatechol as reducing agents. The best alternative depends on the specific application, since these compounds have different reactivity.

Engineering controls are essential where substitution is not possible. These include the use of closed systems and automation, local exhaust ventilation at emission points, and effective general ventilation. These measures help to reduce airborne concentrations of vapours and dust.
Organisational measures include limiting the duration of exposure, providing training to workers (for example on dermal exposure risks), implementing safe handling procedures, and ensuring appropriate cleaning methods that minimise dust generation. Regular monitoring of exposure levels is recommended.

Personal protective equipment should be used as a last line of defence. Special attention should be given to preventing skin contact, due to the ability of the substance to be absorbed through the skin. This includes providing appropriate chemical-resistant gloves and clothing (long-sleeved protective clothing and eye-face protection where splashing is possible), and respiratory protective equipment when necessary.

References: ECHA, IARC, RAC

Limit values

EU
A BOELV is under preparation

Please note that due to transitional periods in the Directive, national OELs might deviate from the BOELV. The overview on national OELs is updated in the 4th quarter every year and may also be the reason for deviation.

 Austria

20mg/m³ (TWA), 40mg/m³ (STEL)
 Belgium
23mg/m³ (TWA)
Bulgaria
EU directive
Croatia
EU directive
Czech Republic
EU directive
Cyprus
EU directive
Denmark
20mg/m³ (TWA), 40mg/m³ (STEL)
Estonia
EU directive
Finland
22mg/m³ (TWA), 45mg/m³ (STEL)
France
20mg/m³ (TWA)
Germany
EU directive
Greece
EU directive
Hungary
EU directive
Iceland
EU directive
Ireland
EU directive
Italy
EU directive
Latvia
EU directive
Lithuania
EU directive
Luxembourg
EU directive
Malta
EU directive
Netherlands
EU directive
North Macedonia
EU directive
Norway
20mg/m³ (TWA)
Poland
10mg/m³ (TWA)m 20mg/m³ (STEL)
Portugal
EU directive
Romania
10mg/m³ (TWA)m 20mg/m³ (STEL)
Serbia
EU directive
Slovakia
EU directive
 Slovenia
EU directive
Spain
23mg/m³ (TWA)
Sweden
20mg/m³ (TWA), 40mg/m³ (STEL)
Turkey
EU directive

References: cancer.gov, EFSA, IARC, EC, NIOSH, OSHA, CAREX

ECHA registration
CAS number 204-427-5
EC number 120-80-9
Annex VI of CLP 1B
Number of registrations 8
Tonnage band registred 1.000 to 10.000 tonnes per annum

The European Chemicals Agency (ECHA) works for the safe use of chemicals. It implements the EU’s groundbreaking chemicals legislation, benefiting human health, the environment and innovation and competitiveness in Europe.

GESTIS Database

The data pool may be used for the purpose of occupational health and safety or to obtain information on the hazards posed by chemical substances.

General facts

Facts about cancer-causing agents:

  • The direct costs of carcinogen exposure at work across Europe are estimated at 2.4 billion Euros per year.
  • Every year, about 120.000 persons get cancer from exposure to carcinogens at work
  • Annually more than 100.000 people die because of work-related cancer.

Table of contents

Sign up for our newsletter to become part of our community. Or follow us on LinkedIn and join the conversation!